Mounjaro vs Zepbound: What's the Difference?

Mounjaro and Zepbound are the same drug, tirzepatide, made by Eli Lilly, in the same doses. The difference between them isn't chemical. It's regulatory: which condition the FDA approved each brand to treat, and what that means for your insurance and your prescription.

The Same Drug, Two Approvals

Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two separate gut hormone receptors rather than one. Eli Lilly sells it as Mounjaro for type 2 diabetes and Zepbound for weight management, but the molecule, the dose strengths (2.5 mg through 15 mg), and the injector pen are identical between the two.

If you're prescribed 10 mg of Mounjaro weekly, it works exactly the same as 10 mg of Zepbound weekly. The only meaningful difference is which condition your prescription is written for, which then determines what your insurance will and won't cover.

What Each Is Approved to Treat

Mounjaro's cardiovascular indication, added in August 2026 based on the SURPASS-CVOT trial, applies to adults with type 2 diabetes who are at high risk for heart attack or stroke. Zepbound's obstructive sleep apnea indication, added in December 2024, made it the first drug ever approved specifically for that condition.

Cost and Insurance

Because Mounjaro is billed as a diabetes medication, it tends to see broader and easier insurance approval, often with prior authorization confirming a type 2 diabetes diagnosis and, in some plans, documentation of trying a first-line drug like metformin first. Zepbound, as a weight-management drug, faces coverage that varies far more by employer and plan, since obesity treatment coverage is inconsistent across US insurers.

List prices for both are similar, and eligible commercially insured patients using manufacturer savings cards can often pay a small fraction of that list price, though eligibility rules and savings caps change and should be confirmed directly with the manufacturer or pharmacy.

Insurance treats Mounjaro and Zepbound differently because of their separate FDA approvals, despite being the same drug.

Switching Between Them

Because the drug is identical, switching from Mounjaro to Zepbound (or the reverse) is straightforward from a pharmacological standpoint and is sometimes done specifically for insurance reasons, for example if a patient has both diabetes and a weight-related condition and one brand is better covered. This should be coordinated with your prescriber rather than attempted independently, since dose continuity and the reason for the switch matter for documentation and coverage.

For the semaglutide-based equivalent of this comparison, see Ozempic vs Wegovy. For how tirzepatide's dual mechanism compares to semaglutide's single mechanism more broadly, see GLP-1 drugs explained.

Why Tirzepatide Tends to Outperform Semaglutide

Both Mounjaro and Zepbound activate the GLP-1 receptor, but they also activate a second hormone receptor, GIP (glucose-dependent insulinotropic polypeptide), which semaglutide-based drugs do not. This dual mechanism is the leading explanation for why tirzepatide has generally produced greater average weight loss in clinical trials, roughly 21% at the highest dose in the SURMOUNT program compared to roughly 15% for semaglutide in the STEP program, though the two haven't been tested head-to-head at every matched dose.

The trade-off is that tirzepatide's dual mechanism has also been linked to somewhat greater relative lean muscle mass loss compared to semaglutide, a pattern covered in depth in GLP-1 drugs and muscle loss. Neither drug is universally "better"; the right choice depends on your diagnosis, tolerance for side effects, and what your insurance will approve.

Choosing Between Diabetes and Weight-Loss Framing

For patients who have both type 2 diabetes and a qualifying weight-related condition, the choice of which brand to pursue often comes down to which pathway your insurance approves fastest and most reliably, since the drug itself is identical either way. Some clinics will start the conversation with whichever brand has the clearest approval path for a given patient, then adjust as needed.

It's reasonable to ask your prescriber directly which brand name they plan to submit to your insurer, and why, since this single administrative decision can meaningfully affect your monthly cost even though the medication in the pen never changes.

Availability and Shortages

Tirzepatide has also faced periods of shortage since 2022, particularly at certain dose strengths, as manufacturing capacity struggled to keep pace with rapidly rising demand for both Mounjaro and Zepbound. Eli Lilly has invested heavily in expanding production, and shortage designations for tirzepatide have eased over the course of 2025 and 2026, though spot shortages at specific pharmacies can still occur.

If you're prescribed one dose and your pharmacy is out of stock, ask your prescriber about checking other pharmacies or Eli Lilly's own direct distribution channels before considering an unverified alternative source.

What the SURPASS and SURMOUNT Trials Showed

Mounjaro's diabetes approval rests on the SURPASS trial program, which tested tirzepatide against both placebo and other diabetes drugs and found meaningful reductions in blood sugar (measured as HbA1c) alongside significant weight loss as a secondary finding. Zepbound's weight-management approval came from the separate SURMOUNT program, which enrolled adults with obesity or overweight, most without diabetes, over 72 weeks.

In SURMOUNT-1, the highest dose of tirzepatide (15 mg weekly) produced average weight loss of roughly 21% over 72 weeks, compared to about 3% in the placebo group. That result, alongside similarly strong data from the SURMOUNT-2 trial in participants with type 2 diabetes, is what drove Zepbound's approval and its reputation as, on average, the most effective FDA-approved weight-loss drug at the time of its launch.

Cash-Pay and Compounded Alternatives

Because list prices for both brand-name drugs remain high for uninsured patients, a cash-pay market has grown around both self-pay vial programs from the manufacturer and compounded tirzepatide from licensed compounding pharmacies. Eli Lilly's own direct-to-patient program, LillyDirect, offers self-pay vials of Zepbound at a lower price than the standard injector pen for patients without insurance coverage.

Compounded tirzepatide from a 503A or 503B pharmacy is legal under specific federal drug-shortage provisions, but it is not the same as an FDA-approved product, and its formulation, purity, and dosing accuracy have not been independently verified in the way Mounjaro and Zepbound have. As with semaglutide, this is worth discussing directly with a licensed prescriber rather than deciding on cost alone.

Common Side Effects Specific to Tirzepatide

Since Mounjaro and Zepbound share the same molecule, their side-effect profiles are identical. The most common are gastrointestinal: nausea, diarrhea, constipation, and vomiting, particularly during the dose-escalation phase in the first several months. Tirzepatide's dual-receptor mechanism does not appear to meaningfully change the type of side effects compared to semaglutide, though some head-to-head trial data suggests slightly different rates of specific complaints between the two drug classes.

Both drugs carry the same boxed warning about thyroid C-cell tumors seen in animal studies. If you're managing gastrointestinal side effects on either brand, see our dedicated guides on GLP-1 nausea and GLP-1 constipation.

Frequently Asked Questions

Are Mounjaro and Zepbound the same drug?

Yes. Both contain tirzepatide at the same dose strengths, made by Eli Lilly. The only difference is the FDA-approved condition each brand name is marketed for.

Which is better for weight loss, Mounjaro or Zepbound?

Since they are the same molecule at the same doses, there's no pharmacological difference in weight-loss effect. Zepbound is the on-label, FDA-approved choice for weight management, which matters for insurance and clinical trial data specific to that use.

Can I use Mounjaro for weight loss if my insurance won't cover Zepbound?

Some doctors prescribe Mounjaro off-label for weight loss, particularly if a patient also has type 2 diabetes, since Mounjaro often has broader insurance coverage. This decision should be made with your prescriber.

Does Zepbound treat sleep apnea?

Yes, Zepbound's FDA approval was expanded in December 2024 to include treatment of moderate to severe obstructive sleep apnea in adults with obesity, making it the first medication approved specifically for that condition.

Sources and References

1. Drugs.com — Zepbound vs Mounjaro: Complete Comparison Guide
2. GoodRx — Mounjaro vs. Zepbound: Using Tirzepatide for Diabetes vs. Weight Loss
3. Drugs.com — Zepbound (tirzepatide) prescribing information
4. FDA — Mounjaro cardiovascular indication approval, August 2026